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Reply to Reviewers’ and Editorial’s comments
Review Editor: Rehm, Bernd
There were no comments from the Review Editor.
Reviewer #1
This is a well-done manuscript. It is scientifically sound, covering all current and latest 
information regarding BC applications in biomaterials and tissue engineering. There are some 
minor changes that need to be addressed: 
R.: We thank the reviewer for the recommendation and time spent in reviewing our work, and 
for the insightful commentaries that will undoubtedly help us to improve the overall quality of 
the manuscript.
1. combining section 2.1 and section 2.7.3 to be 2.7.3 since both are related to skin and wound 
healing. 
R.: As suggested, sections 2.1 and 2.3.7 were combined into section 2.2.1. Please, note that with 
this change, two tables and two figures switched places: Table 1 is now Table 2, Table 2 is now 
Table 1, Figure 1 is now Table 2 and Figure 2 is now Table 1.
2. Sections 1.1 and 1.2 are too long given that most of reviews on BC start with these sections 
and the same information is being repeated in here too. It is uninteresting and making the 
paper less focused. One way to do this is to refer readers to other insightful reviews on BC for 
physical properties and synthesis.
R.: We thank the reviewer for the suggestion. As recommended, sections 1.1 and 1.2 were 
shortened by removing some information that was not crucial for the topic of the review. There 
were already some referenced reviews cite in our review that better cover the production of BC 
and its properties.

































































The review summarizes the research on three important aspects of bacterial cellulose. There 
are certain grammatical errors. Please check the references with respect to author names and 
sequence.
R.: We thank the reviewer for the recommendation and time spent in reviewing our work, and 
for the insightful commentaries that will undoubtedly help us to improve the overall quality of 
the manuscript.
As suggested, grammatical errors in the manuscript were corrected and where needed, italics 
were added. In addition, the references were checked, and it was noticed an error in the authors, 
and some errors in the pagination of the articles. Their respective corrections were performed.
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Bacterial cellulose (BC) is a nanocellulose form produced by some non-pathogenic 
bacteria. BC presents unique physical, chemical and biological properties that make it a 
very versatile material and have found application in several fields, namely in food 
industry, cosmetics, and biomedicine. This review overviews the latest state-of-the-art 
usage of BC on three important areas of the biomedical field, namely delivery systems, 
wound dressing and healing materials, and tissue engineering for regenerative medicine. 
BC will be reviewed as a promising biopolymer for the design and development of 
innovative materials for the mentioned applications. Overall, BC is shown to be an 
effective and versatile carrier for delivery systems, a safe and multi-customizable patch 
or graft for wound dressing and healing applications, and a material that can be further 
tuned to better adjust for each tissue engineering application, by using different methods.


































































The biomedicine research field aims to find biomimetic structures and processes that aids 
to surpass and improve the actual shortcomings faced in the treatment of illnesses and 
diseases, leading to great investment in the research in this field and related areas.[1] As a 
result of this intensive investigation, a great diversity of materials have arisen as potential 
candidates for biomedical applications. Among them, natural biopolymers such as 
bacterial cellulose (BC) have found a large diversity of applications and have been 
broadly studied, due to their similarities to native tissues.[1,2]
Cellulose, a linear biopolymer composed by glucose units linked through β(1,4) 
glycosidic bonds,[3] is an intrinsically biodegradable and biocompatible polymer that is 
widely known as the most abundant polymer in the planet.[4,5] Cellulose is mainly found 
in the plant's cell wall and is one of its main structural elements. However, this biopolymer 
can also be synthesized by tunicates, algae and some bacteria.[6,7] Its physical properties, 
such as molecular weight, degree of crystallinity, and crystalline state are highly variable 
and dependent on the respective source and extraction procedure.[5] Other characteristic 
properties, such as biodegradability, chirality, hydrophilicity, and the ability for chemical 
modifications are imparted by its molecular structure.[4]
Among the different cellulose sources abovementioned, cellulose produced by 
nonpathogenic bacteria has been attracting increasing interest, especially in 
biomedicine,[8] due to its unique properties (described in detail in Section 1.2.). Thus, this 
review aims to provide an overview of the recent advances in the use of BC in biomedical 
applications. To provide a comprehensive understanding of the topic, we will first briefly 
describe the BC biosynthesis and properties.
1.1. BC biosynthesis
Several non-pathogenic bacteria are able to produce BC, however, Komagataeibacter 
medellinensis (former Acetobacter xylinum) is known as the most efficient producer.[1,6,9–
12] On its own, the biosynthesis of cellulose can serve several purposes to the bacterium, 
from physiological, mechanical and chemical stability protection, to the improvement of 
interactions and nutrient diffusion.[1] BC synthesis starts on the cellular membrane, where 
chemically activated glucose is polymerized by cellulose synthase.[6,10] On the 
extracellular space, the glucose chains are organized into parallel structures through van 
der Waals and hydrogen bonds, forming fibers.[1,6,13,14]

































































BC production is mainly performed in nutrient-rich culture media, either static or agitated. 
These two methods for BC production originate structures with distinct morphologies, 
thus the choice of the method used will depend on the final application envisaged.[14–16] 
In the production of BC under static culture, a pellicle is originated, while in an agitated 
culture, suspended fibers, irregular pellets, or even spheres are produced.[14–16] Although 
agitated culture is faster relatively to static culture, the production yields are lower and 
there is a higher probability of mutations in the bacteria.[14,16] By using more complex 
methods, BC can also be produced in the form of hollow spheres, namely through the use 
of microfluidics,[17] or water-in-oil emulsion techniques.[18] A novel and innovative way 
to obtain fine-controlled and complex shapes of BC were recently described by Schaffner 
et al.[19] They used 3D bioprinting where a biocompatible hydrogel, with adjusted 
rheological properties, allowed the immobilization of Acetobacter xylinum. This bacteria-
containing hydrogel was then printed into a predesigned 3D shape. The following 
incubation enabled the formation of BC scaffolds on nonplanar surfaces. This new 
strategy can open new horizons regarding the development of scaffolds and membranes 
with complex architectures for divers  types of biomedical applications, not accessed by 
common techniques.
1.2. BC properties
BC exhibits superior properties that make it suitable for use in biomedical applications, 
namely its higher purity, the ultrafine network structure, higher crystallinity, and 
improved mechanical properties, which arise from the nanofibrils 3D network.[6–9,11] The 
resultant nanofibers have a high surface area, which altogether with the hydrophilic nature 
of BC, resulting in a high water holding ability and adhesion.[14] Several properties must 
be considered in the design of a biomaterial, namely the biocompatibility, the ability to 
promote cellular interaction and the development of the tissue, the biodegradability and 
bioabsorbability, interconnected porous structure, and good mechanical properties able to 
support loads and high resistance to wear. These parameters will be briefly addressed 
below; however, since this is not the focus of this review other reports can be accessed to 
obtain more detailed information on these topics.[1,20]
Important features that make BC biocompatible is its chemical nature and its nanofibrillar 
architecture that resembles an extracellular matrix (ECM) component, specifically the 
collagen.[21] Moreover, the polysaccharide nature of BC reduces or eliminates the 
immunogenic response.[20] Several studies proved the biocompatibility of BC-based 

































































materials in diverse biomedical applications,[2,20,21] as well as low genotoxicity and 
cytotoxicity.[22]
In some types of biomedical applications, such as skin, wound healing and bone scaffolds, 
the lack of bioabsorbability can be a desirable property.[10] Despite the existence of some 
slow non-enzymatic hydrolysis of cellulose, the human body is not able to degrade 
cellulose due to the absence of cellulases,[10,20] making BC suitable for use in applications 
that requires long term support.[1] However, to extend the range of applicability of BC, 
several attempts have been made to make BC bioabsorbable, for example, by oxidation 
of cellulose,[20,23,24] or by incorporation of cellulases within BC.[25,26]
The control over the macro, micro, and nanostructures is another important feature to take 
in consideration in different biomedical applications. Important properties in the micro 
and nanostructure are the porosity, surface chemistry, and fiber orientation.[20] Some of 
these characteristics are not the ideal for every application, and sometimes it is necessary 
to tailor BC for a specific use. This can be accomplished through the modification of BC. 
There is a great diversity of modifications that can be applied to BC, which can be 
grouped in two distinct classes: in situ and ex-situ modifications,[27,28] consisting 
respectively in the incorporation of exogenous molecules that are added to the culture 
medium during BC biosynthesis,[29–33] or performed after the BC is produced and purified, 
and can be carried out either by chemical or physical methods.[28] Porosity is a great 
concern in applications such as the development of scaffolds for cell growth. However, 
BC is naturally produced in the form of a dense mesh, hindering cell migration into the 
material. Thus, several approaches have been used to increase porosity on BC membranes, 
mainly through the use of porogens (i.e., materials added to the culture media, that 
become incorporated in the BC membrane, being later removed, leaving pores behind, 
without significantly damaging the material).[34] The high density of hydroxyl groups at 
the BC surface, making it simple to chemically modify this substrate. Therefore, there 
have been several attempts to change the surface chemistry of BC, taking advantage of 
this specific property. Oxidation mediated by (2,2,6,6-Tetramethylpiperidin-1-yl)oxyl 
(TEMPO), phosphorylation, and succinylation are examples of this type of 
modifications.[1,35] Usually, BC nanofibers are randomly orientated, however, there have 
been several attempts to align the BC nanofibers, namely using microfluidic channels,[36] 
a scaffolding of nematic ordered cellulose with aligned cellulose fibers,[37] or external 
electromagnetic fields[38] to direct the bacteria motion and achieve fiber alignment. 

































































Naturally, BC exhibits high mechanical properties,[4,9,12] such as Young’s modulus of 
about 118 GPa for a single BC filament, tensile strength of 200-300 MPa, and a stress-
strain behavior similar to that of the soft tissues.[4,9,10,12] For these reasons, BC is widely 
used as reinforcement material and is a good candidate for applications desiring a high 
mechanical performance material.[10,12]
2. Applications
2.1. BC in systems for the delivery of drugs and other molecules
As a result of the non-bioabsorbable nature of BC in the human body, the use of BC as 
delivery systems for drugs and other molecules have been limited essentially,[39] as can 
be observed from Table 1, to dermal patches[40] and oral capsules.[41,42] For the 
development of dermal patches, the porosity of BC is easily exploited to load drugs with 
different features, ranging from antibacterial activity[43] to anticancer properties.[44] 
Additionally, BC can be further optimized by chemical modifications with other 
(bio)polymers, or by producing BC-based materials, to better control its cargo release, 
burst,[18] or sustained release,[45] and even responsive releases to pH,[46] temperature[47] or 
electromagnetism.[48] For the development of oral formulations, BC has been used in 
combination with other biopolymers for a controlled release of the drug within,[41] e.g. for 
the oral delivery of insulin,[42] and hydrophobic and hydrophilic drugs alike.[49]
Most dermal patches are prepared by simply soaking a pure BC membrane,[40,43] or a 
BC-based composite,[50] in a solution of the compounds of interest. In order to achieve 
multiple desired results, these membranes can be loaded with more than one compound 
at once. Morais et al.[51] loaded BC membranes with ionic liquids based on phenolic acids, 
for the development of patches for skin treatment. Biological assays showed that these 
patches have both high antioxidant and anti-inflammatory activities, in addition to 
biocompatibility and sustained release of its cargo. Other study that demonstrates that a 
BC membrane can have multiple actions, is the study performed by Badshah et al.,[52] 
where BC was modified with acetic anhydride, to be able to be loaded with one of two 
drugs with very different natures, one poorly water-soluble, and the other highly 
water-soluble. Before the reaction, the BC membranes were soaked with acetic acid. Then, 
the membranes were impregnated with either an acetic acid solution of the poorly water-
soluble drug or an aqueous solution of the water-soluble drug. Furthermore, the drug 

































































loading capacity and drug release rate where further controlled by the drying method of 
the membranes (freeze-drying vs. oven drying). In another study,[50] two different 
molecules were loaded in a BC-based composite, specifically serum albumin, which 
modulated the release of the other molecule, levofloxacin, reducing its cytotoxicity to 
undetected levels, without losing its antibacterial activity. These three mentioned 
studies,[50–52] are a great example of the versatility of BC to further develop dermal 
patches for drug delivery systems, that can be laden with different molecules while 
maintaining properties of interest.
Studies of drug delivery systems for oral administration also benefited from exploiting 
BC characteristics. For the first time, BC capsules for oral administration were prepared 
by Ullah et al.[41] Capsule shells of pure BC or BC conjugated with starch, 
hydroxypropylmethylcellulose or carboxymethyl cellulose were prepared and used for 
encapsulation of salbutamol sulfate. The capsules of pure BC demonstrated a burst release 
of the drug, whereas the ones formulated with other polymers showed controlled drug 
release (6h for the one formulated with carboxymethyl cellulose). Additionally, the 
capsules formulated with carboxymethyl cellulose showed to better prevent drug leakage 
at a lower pH. This study showed the versatility of BC for either burst or controlled release 
of a contained drug. In order to prepare a tablet for oral administration of both water-
soluble and poorly water-soluble drugs (tizanidine and famotidine, respectively), 
Badshah et al.,[49] used BC as the sole excipient, compared to the multi-excipient 
commercial formulations. The authors prepared different formulations of drug-loaded 
discs by only changing the loading and drying methods. The ones containing the water-
soluble drug were immersed in an aqueous solution of the drug, while the ones containing 
the poorly water-soluble drug, were immersed in an acetic acid-methanol solution of the 
drug. All formulations showed a superior burst release for both drugs, contrasting to the 
slower release of tizanidine by the commercial product. Taking examples from these 
studies,[41,49] novel formulations can be designed to prepare drug delivery systems for oral 
administration that need to exploit the properties of BC, such as the ones presented: water 
insolubility and high water-holding capacity, ultrafine fiber network and high porosity, 
and ease of production into desired shapes.
2.2. Tissue engineering and regenerative medicine
2.2.1. In vivo wound dressing, healing and skin tissue engineering studies

































































There are various well-known characteristics of BC that can be exploited to develop novel 
dressings for wound healing, being it full-thickness wounds or third-degree burns, where 
the extent of these injuries past the dermis and epidermis into subcutaneous tissue. Some 
of these well-known BC characteristics are the biocompatibility, the mechanical 
resilience, the easiness to be laden with drugs or nanoparticles, and the ability to moist 
the wounded area, while absorbing formed exudates. It is also a physical barrier against 
microbes and other external aggressions, while allowing gas exchange. It also has the 
capacity of being removed from the wound without pain and without damaging the newly 
formed tissue.[10,39,53] Additionally, when used as a wound dressing, BC optical 
transparency provides the possibility of using laser-based imaging diagnosis, such as 
multiphoton tomography, optical coherence tomography, and confocal laser scanning 
microscopy, allowing a n n-invasively follow-up of the wound healing development.[54]
The incorporation of drugs,[55,56] nanoparticles,[57,58] biopolymers,[59,60] or even cells[61] 
that either have antimicrobial activity or induce the severed tissue regeneration to be faster, 
into BC based materials, demonstrated synergistic activity. Table 2 summarizes the types 
of BC-based dressings developed during the last years, as well as the outcomes of the in 
vivo tests. These studies were mainly performed in full-thickness wounds, third-degree 
burns, and femoral artery injuries, and the performance of each formulation was evaluated 
through histological imaging, wound closure measurement for skin wounds, and blood 
loss for the femoral artery injuries.
Research on quenching uncontrolled hemorrhages has also been done in the past few 
years, because inexpensive hemostatic agents that can be easily applied, with good 
effectiveness at stopping hemorrhages, are still to be achieved.[62] With this as objective, 
biocomposite dressings of BC and chitosan with an electrospun upper layer of silk fibroin 
or silk fibroin/phosphatidylcholine were prepared.[62] Some of these bilayer dressings 
were loaded with different hemostatic agents (kaolin, vitamin K, and protamine sulfate). 
Comparative studies were made against standard gauze on Sprague-Dawley rats. All 
dressings except the kaolin-loaded one, showed satisfying results regarding the 
quantifications of the activity of lactate dehydrogenase, an enzyme released during tissue 
injury, the time elapsed to hemostasis, blood loss and animal mortality were evaluated. 
This study was repeated by the same group, but this time using diabetic Sprague-Dawley 
rats as animal models,[63] due to the risk of bleeding complications that arise from 
hemostatic irregularities induced by this disease. The prepared dressings and the executed 

































































procedures were the same as the ones in the former study, showing once more the 
effectiveness of these hemostatic agents, with extremely similar results in terms of 
mortality, blood loss, time to hemostasis, and lactate dehydrogenase activity, of all 
prepared formulations, except for the one loaded with kaolin.
The nanostructure of BC-based formulations was reported to be an important 
characteristic for the quality of the wound healing process, by using patterned BC 
membranes that were prepared on top of soft templates with grooves of different width 
sizes (10, 30 and 50 μm), and all with a depth of 10 μm.[64] Since the in vitro studies with 
these patterned membranes showed better results for the ones with 10 μm thickness, these 
were furtherly used on in vivo studies, where the wounds on the rats treated with this 
patterned membrane showed to be healed after twenty-one days, with a scar with 
thickness half of the one formed on the untreated wounds and the wounds treated with 
gauze (scar thickness of less than 300 μm vs. 600 μm), and around 100 μm less than the 
scar formed on the wounds treated with non-patterned BC. 
Another study that showed the importance of the nanostructure of the dressing was when 
hollow BC microspheres were produced with the objective of creating an injectable 
scaffold for wound healing.[17] In vivo studies were performed on rats by inflicting a 
wound on the back of each animal, and then by covering the non-control specimens with 
a bulk BC membrane, non-hollow BC microspheres or hollow BC microspheres. This 
study reported that after 7 days, there was no difference in the wound size between the 
controls and the ones covered with bulk BC. Both rat populations showed to have a better 
recovery when microspheres were used with the best results observed for the hollow ones. 
The authors state that this difference in wound recovery speed is due to the higher porosity 
observed on the hollow BC microspheres.
Similarly to this last study, a biocomposite was prepared by incorporating gelatin 
microspheres within recovered BC, followed by the dissolution of the gelatin, leaving 
behind sponge-like hollow spaces within the recovered BC, while covering the same BC 
with a layer of gelatin, increasing the biocompatibility of the material.[62] Using this 
biocomposite and an untreated BC membrane, the in vivo studies were performed, first 
by inflicting a full-thickness wound on each animal model, and then by covering the 
wound with the different dressings. After 2 weeks, the wounds treated with the composite 
dressing were healed, comparing to the 60% wound closure of the ones treated with BC 

































































only. This study, once again, showed the importance of the existence of pores on wound-
healing patches. However, since the prepared composite also had gelatin covering the 
surface of its pores, it would be beneficial to additionally compare it to a gelatin-covered 
BC membrane.
BC-based dressings continue to show high healing performance over conventional 
materials, such as gauze, without considering minimizing the pain suffered by the patient 
both during the first days after the wound was inflicted or at the time of the dressing 
removal.[65] During the last years, the studies using BC as a base for the development of 
wound healing materials kept showing its versatility. BC can be loaded with different 
components that can be either antimicrobial or regeneration-inductive agents. Easily, BC 
can have its pH adjusted in order to provide a better environment for tissue 
regeneration.[66] Furthermore, BC can be designed to be a structure which physical and 
chemical conditions can be adjusted, improving the extracellular environment, leading to 
a faster wound healing.
Similarly to wound healing applications, skin tissue engineering comprises the restoration 
of the two main layers of skin, the epidermis and the dermis. The nanofibrils of BC 
hydrogels resemble the fibrillar component of the native ECM. Furthermore, BC has great 
retention moisture content ability and suitable mechanical properties. As a result of its 
similarity with skin, BC has been widely used in the reconstruction of this tissue.[67]
A novel composite aiming to enhance the adhesion of skin fibroblasts on BC surface was 
developed by the in situ or post modification of BC with keratin.[68] The in situ approach 
consisted in the addition of keratin to the bacteria culture medium. Moreover, the post-
modification involved the impregnation of keratin in the BC membrane after its 
biosynthesis and purification. Both approaches produced suitable composite materials, 
which demonstrated a good attachment of dermal fibroblasts and maintenance of original 
epithelial morphology of keratinocytes on the surface of BC-keratin composites.
Despite the as-referred advantages of BC for skin applications, its opaque form limits its 
use in daily life applications. TEMPO-mediated oxidation of BC originates a transparent 
form dispersed in water. To evaluate the suitability of TEMPO-mediated BC nanofibers 
for application in the skin, Jun et al.[69] studied its physical properties and filtrating 
particulate matter ability on a porcine skin model 


































































Figure 1). TEMPO-mediated BC nanofibers exhibited adherence to the skin surface, and 
high tensile strength and high water-holding ability. Moreover, it prevented the direct 
adhesion of particulate matter on the skin.
2.2.2. Cardiovascular implants
BC is a material of interest to develop cardiovascular implants, because of its already 
described physical and biological properties, as well as the possibility to produce it in 
various forms and shapes that better suit the application, either to produce grafts, patches 
or hydrogels for either vascular grafting or regeneration.
While there are gold-standard materials to produce large and medium-diameter vascular 
grafts, there is still a need to develop a small-diameter vascular graft (<6 mm), especially 
ones with long-term patency.[70] As a result of the innate characteristics of BC as a 
biomaterial, it has been used to prepare small-diameter vascular grafts, by using different 
techniques. These techniques can be as simple as piercing BC with a metallic skewer with 
the right diameter and use it as a mold,[70] or cultivating the BC inside a double cylinder 
bioreactor.[71] More elaborated techniques were also reported, such as cultivating BC 

































































layer-by-layer around a guide bar,[72] or preparing a self-rolling BC membrane with 
shape-memory.[73]
Following the simplest and the most inexpensive method, based on the use of a skewer,[70] 
pure BC was used to prepare the graft, showed to be patent after one month of in vivo 
implantation. However, after two months the grafts were obstructed by thrombi and the 
experiment was terminated. The authors suspected that the obstruction was due to animal 
handling, meaning that more studies needed to be performed.
In the study where BC was produced within a double cylinder bioreactor,[71] the authors 
prepared a BC-heparin biocomposite that showed better characteristics for a patent graft 
than pristine BC: anticoagulation activity, less platelet adhesion, very slow plasma 
clotting, and good cell viability. Since this biocomposite showed inferior mechanical 
properties, the authors further prepared a BC-heparin-chitosan biocomposite, with 
mechanical characteristics that surpassed the ones from the previous grafts. However, it 
showed slightly inferior cell viability. The authors describe both biocomposite grafts as 
viable for the development of small-diameter vascular grafts and added that the latter graft 
was considerably interesting due to the chitosan bioresorbability, leading to a slow release 
of heparin.
In another study where the BC graft was produced layer-by-layer,[72] the aim was to 
prepare a graft with a smoother and compacter inner wall than a graft where the 
morphology of the inner wall was not controlled. Results showed increased patency from 
67 to 80% in 9 months period, while an antiplatelet drug was being orally administrated 
to the animals. Since it was a proof-of-concept study, where few animals were used and 
few characterizations were performed, the authors stated that a more extensive study was 
needed, using this promising technique of small diameter vascular graft production. 
Using a totally different method to prepare a small diameter shape-memory BC tube,[73] 
as shown in Figure 2a and Figure 2c. This can be further exploited to load the same graft 
with different cells (Figure 2b) that will stay in layers after the membrane is rerolled 
(Figure 2d), which is a phenomenon of interest if one of the aims is to better mimic the 
different layers of a vessel. After in vivo implantation of a tube not loaded with cells, 
blood flow was confirmed to pass through the tube, and after 3 days, ultrasound images 
revealed that it was not possible to perceive the boundary between the tube and 
surrounding tissue, meaning that possibly the tube was encapsulated by the surrounding 

































































tissue. After 21 days, the tubes were excised, and it was observed the absence of thrombi 
formation and the absence of immune cells between the layers of the tube. With these 
promising results, the authors stated that this graft can be further exploited to develop 
small-diameter vascular grafts and that further experiments with cell-laden grafts must be 
performed in the future.
Aiming at quickening the re-endothelization of a severed vascular tissue, BC hydrogels 
with magnetic properties have been developed and characterized, since this kind of 
materials can recruit tissue-regenerating cells.[74,75] The magnetic BC hydrogel was 
prepared by a simple method consisting of the immersion of the BC hydrogel in a solution 
containing iron II and III salts, following by in situ synthesis of magnetic iron 
nanoparticles. Even though these type of nanoparticles are used in magnetic resonance 
imaging, in higher concentrations they disrupt the mitochondrial respiratory chain and 
start to generate radical oxygen species (ROS).[74] In order to evaluate the cell 
recruitment/cytotoxicity ratio of the magnetic BC hydrogels, a gradient concentration of 
magnetic Fe nanoparticles were prepared within the BC hydrogels,[75] and it was observed 
by in vitro studies that for concentrations as low as 25 mM there was a substantial cell 
recruitment, while maintaining a cell viability similar to the one of unmodified BC. 
Furthermore, for higher concentrations of these nanoparticles, cytotoxicity was 
observable, where for concentrations of nanoparticles of 100 mM the cell viability was 
very low. In a different study,[74] to prevent the induction of ROS production by these 
nanoparticles, magnetic BC was coated with poly(ethylene glycol) (PEG) by immersion. 
In vitro ROS quantification was observed to be around half on the PEG-coated magnetic 
BC, as compared to the uncoated one.
In a different vein, Kołaczkowska et al.[76] developed a BC-based regenerative implant to 
be used in cardiac and vascular surgeries by preparing several biocomposites of 
BC/hyaluronic acid/poly(vinyl alcohol) (PVA), using different methods: addition of 
hyaluronic acid or PVA to the BC culture media; BC impregnation with aqueous solutions 
of hyaluronic acid or PVA; BC impregnation in a given solution for 2 hours at 80 ºC; BC 
impregnation in a given solution and autoclaving it for 20 minutes at 121 ºC. After 
physical and biological characterization, the most promising patch was used in animal 
vascular surgery, showing greater durability than animal tissue, good biocompatibility, 
low thrombogenicity, and low hemolysis. However, the patch showed poor cell adhesion. 

































































This study was the first step for the development of a scaffold for regenerative medicine, 
and more studies need to be performed in the future.
BC has fantastic characteristics for tissue engineering applications, yet it lacks the 
capacity to develop proper vascularization, leading to cellular apoptosis. To attenuate this 
problem, Wang et al.[77] developed a porous scaffold biocomposite of BC/gelatin, 
containing silk fibroin nanoparticles loaded with vascular endothelial growth factor 
(VEGF). The in vitro experiments demonstrated a continuous release of VEGF for 28 
days and increased cell proliferation. Additionally, the in vivo experiments showed a 
substantial angiogenesis increase in the animal tissue patched with the developed scaffold.
2.2.3. Dentistry applications
For dental extraction and mucosal transplantation applications, bioabsorbability under 
physiological conditions and antibiotic loading are desirable. In this context, Weyell et 
al.[78] studied the degradation and doxycycline release from BC membranes with different 
oxidation degrees. The BC oxidation was achieved with periodate and was performed for 
several reaction times and temperatures. The authors found that at a periodate 
concentration of 0.14 mol/L, a temperature of 25 °C and 8 h of reaction, the membrane 
obtained was partially degraded and still did not compromise the loading and retention 
capacity of the dressing. Moreover, the antimicrobial activity of the oxidized BC 
membranes loaded with doxycycline maintained its efficiency against pathogenic oral 
bacteria and exhibited biocompatibility with L929 mouse fibroblasts.
Besides BC’s chemical, physical and mechanical properties, it was previously reported 
that the presence of BC nanowhiskers quicken the hardening process of silicate cements, 
originating suitable composites for application in endodontics.[79] To further study the 
BC’s potentialities in the endodontics field, namely its ability to improve the binding 
properties of mineral cements, Voicu et al.[80] prepared BC-silicate composites cements 
that exhibited a faster setting time and high mineralization process in in vitro tests. Cell 
studies indicated that mesenchymal stem cell cultures adhered and proliferated and that 
there was no oxidative stress. This behavior made the composite developed, highly 
interesting for endodontics applications, namely in root channel obturation, perforated 
channel filling or dentine mineralization.
As a result of its self-attachment to surfaces, flexibility, and softness, BC can also be a 
good candidate in other dental medicine applications, such as temporal implant in dental 

































































extraction alveoli or wound dressing after mucosal implantation.[78] However, although 
the recognized improved epithelialization and decreased inflammatory reactions during 
the use of BC-based periodontal dressing materials,[81,82] the number of studies of its 
application in this area is scarce. 
2.2.4. Urethral implants
The urethra, as a hollow organ exhibits an asymmetric structure, which can be divided in 
a stratified epithelium that acts as the barrier of the urethra, and in an organized 
subcutaneous layer that contains muscle cells and fibroblasts, providing strength and 
flexibility.[83] There are several conditions and injuries that lead to a loss of urethra 
function. The scaffolds designed for urethral tissue engineering must respond to three 
basic principles: (1) mimic the ECM; (2) mimic the natural asymmetric structure 
accommodating a large number of cells in one side and acting as a barrier on the opposite 
side; and (3) be capable of resist to the mechanical requirements during the formation of 
the new tissue.
BC is a great candidate for urethral tissue engineering due to the mechanical and 
biological properties already mentioned, namely the similarities between the BC structure 
and the ECM, which may improve the cell adhesion and proliferation.[20] Lima et al.[84] 
and Maia et al.[85] studied the application of pure BC membranes as urethral reinforcement 
in animal models, namely in Wistar rats and rabbits, respectively. In both studies, the BC 
membrane was well integrated into the urethral wall. Furthermore, Lima et al.[84] reported 
the remodeling and strengthening of the urethral wall of the Wistar rats. Maia et al.[85] 
found that the BC membrane was biocompatible, however, they also observed a decrease 
in the urethral wall thickness after 14 weeks of implantation and this way they were not 
able to conclude about the ability of BC to induce urethral reinforcement. More studies 
on this topic are needed to construct a higher level of evidence about the effect of BC 
membranes in urethral reinforcement.
The compact structure of pristine BC can lead to a lack of cell migration, penetration, and 
ingrowth.[86] To overcome this issue, Lv et al.[87] developed a nanofibrous scaffold by 
gelatinization of potato starch in the culture medium, and posterior addition of 
Gluconacetobacter xylinus to interrupt cellulose formation during static culture, creating 
more free spaces in the cellulose network. The prepared scaffold was cultured with 
muscle cells and then implanted in dog urethral defect models, exhibiting an enhanced 

































































wound healing of the tissues. With the goal of surpassing the as-referred disadvantage of 
BC, the same team developed a bilayer scaffold constituted by a microporous network of 
silk fibroin (SF) and a nanoporous network of BC.[88] The introduction of SF in the 
scaffold allows the ingrowth of the host tissues, while BC acts as a membrane to the 
retention of urine. The developed scaffolds exhibited biocompatibility and the ability to 
support cell adhesion and proliferation.
2.2.5. Neural implants
Injuries of the nervous system are a very serious concern. Nowadays, the gold standard 
for the regeneration of nerve injuries are the nerve autografts, a nerve collected from a 
less important part of the body. However, application of autografts presents several 
drawbacks, such as the need for a second surgery to harvest the nerve, the donor site 
morbidity in the secondary surgical site, the availability of donor tissue, and the low 
efficacy of treatment.[89,90] Therefore, the last years have witnessed many efforts to 
improve neural regeneration, with tissue engineering playing a prominent role in the 
advances made in this field.
The materials used for such applications should present a 3D structure resembling the 
ECM and properties that enables the cellular attachment.[89] Regarding these properties, 
BC has merged as a promising material in this field. For example, Geisel et al.[91] 
produced BC with controlled topographies through bacterial culturing and molding with 
patterns. Subsequently, they studied the influence of BC controlled topographies in neural 
stem cells growth and differentiation and found that when cultured in randomly orientated 
BC, the neurons exhibited a higher differentiation and surviving rate. The authors 
attributed this effect to the ECM like structure of the randomly orientated BC that became 
very smooth and dense surface in structured BC. Furthermore, they found out that 
randomly BC cultures presented a higher cell density than ECM-coated cover slips.
In a different study Altun et al.[92] prepared bioinspired scaffolds by electrospinning of a 
-caprolactone/BC blend. The prepared scaffolds exhibited a well-defined and 
interconnected network with hollow micro/nanobeads, which closely reminds 
neurological networks, and showed to be non-cytotoxic, biocompatible and promoted cell 
adhesion. The dorsal root ganglia cells exhibited biocompatibility with the scaffolds since 
almost all of them were sticky and axon extended. Furthermore, the scaffolds presented 
a high supportive effect of dorsal root ganglia cells and enhanced neurite outgrowth, 

































































proving its potential to the creation of 3D guidance scaffolds to stimulate nerve 
regeneration.
A 3D-scaffold was prepared by Kim et al.[93] by introducing graphene oxide (GO) 
nanoflakes into BC culture media, obtaining a nanocarbon hybridized structure. This 
process introduced structural modifications in the crystalline cellulose nanofibril and in 
their 3D-assembly. GO-BC scaffolds exhibited increased ability to support the primary 
neuronal cell culture in a way that resembles the in vivo environment in brain tissue. 
Furthermore, neuronal activity and long-term culture viability were also preserved.
Bioabsorbability is a key property for a neural scaffold.[89] In this context, Hou et al.[94] 
evaluated BC scaffolds with different oxidation degrees caused by ex-situ modifications 
through oxidation with NaIO4 to improve the bioabsorbability of BC. They obtained BC 
scaffolds with suitable mechanical properties, high porosity, and interconnected pores, as 
well as improved bioabsorbability. These scaffolds showed cellular and blood 
compatibility, demonstrating to be a potential candidate for application in peripheral 
nerve repair.
Epidural fibrosis and adhesion affect several nerves and cause recurrent pain in the back 
or limbs. The solution to this problem passes through the development of barriers to 
inhibit the compression of neural structures by postsurgical fibrosis. Wang et al.[95] 
developed a barrier that consisted of a membrane of BC with exosomes from human 
umbilical cord mesenchymal cells (HUCMSC-Exos). The obtained membrane exhibited 
a 3D network structure, suitable mechanical properties, no cytotoxicity and 
biocompatibility in vivo. Furthermore, the membrane inhibited epidural fibrosis and 
peridural adhesions.
In a different approach, Yang et al.[96] took advantage of the similarities between the 
mechanical properties of BC and brain tissue, to produce a biocompatible neural interface. 
They developed electrodes by electron beam evaporation of gold in a BC substrate. These 
electrodes exhibited lower bending stiffness than Au-polyamide electrodes, high 
durability and ability to record brain electric activity, demonstrating its potential to treat 
neurological disorders.
2.2.6. Artificial cornea and retina 

































































Retinal pigment epithelium (RPE) consists of a monolayer of pigmented and polygonal-
shaped epithelial cells, which carry out several essential tasks for visual function.[97] The 
most common cause of blindness worldwide is the age-related macular degeneration, 
which is related to the degeneration of the retina.[98] The replacement of unhealthy RPE 
by healthy stem cell-derived RPE-like cells, transplanted as a single epithelial sheet on a 
carrier substrate has shown to be a promising therapy.[99] The requirements of an ideal 
carrier for RPE transplantation are very complex, therefore the development of viable 
substrates has not yet been successful. Gonçalves et al.[100] developed an acetylated 
bacterial cellulose (ABC) substrate coated with urinary bladder matrix (UBM) for the 
adhesion and proliferation of RPE cells. The prepared substrates allowed the development 
of a cell monolayer, phenotypically like natural RPE cells (polygonal shaped morphology 
and microvilli), able to express metabolic (RPE65) and cytoskeletal (ZO-1) essential 
proteins. The produced composite substrates also exhibited low swelling effect, high 
mechanical strength, and non-pyrogenicity. Altogether, these characteristics make ABC 
substrates promising cell carriers in RPE transplantation.
Another common cause of visual injury or blindness worldwide are the cornea 
opacities.[101] The most widely used treatment for cornea opacities is corneal grafts. 
However, the xenografts currently applied exhibit rejection issues after 4 to 5 years of 
treatment, and allografts, besides originating the best results, have limited supply.[102] 
Biopolymers are gaining more attention as potential materials for replacement of corneal 
tissue, by recovering the proper refractive status of the eye. Due to its properties, BC is a 
potential candidate for cornea replacement. However, BC exhibits limited transparency 
and is inelastic.
Aiming at improving its mechanical and optical properties, BC was combined with 
polycaprolactone (PCL), which is a biodegradable, bioabsorbable, biocompatible and 
viscoelastic polymer. The composites were prepared by impregnation of the PCL acetone 
solution into a dried BC membrane. The BC-PCL composite membranes showed to have 
improved transparency (transmittance of 85 %), be biocompatible, and more 
malleable.[103,104] To further evaluate the potential clinical applications of these 
membranes, Sepúlveda et al.[105] implanted both BC and BC-PCL composite membranes 
in rabbits’ cornea. Both BC and BC-PCL implants remained stable in corneal tissue and 
protected the ocular surface during the follow-up time (45 days). However, it was 
observed as a chronic inflammatory condition, incomplete epithelialization over the 

































































implanted membranes, and disorganized collagen fibers, indicating that any of the 
implants tested was unsuitable for the replacement of rabbits’ corneal tissue.
2.2.7. Soft Tissues
Nowadays, prosthetic meshes are commonly used in abdominal wall hernia surgery, and 
this practice is known to reduce the rate of postoperative recurrence. Expanded 
polytetrafluorethylene (ePTFE) is among the synthetic prostheses used for this purpose; 
however, it shows some limitations, such as the lack of incorporation in the host tissues 
and seroma formation.[106] BC hydrogel was previously proved to be a suitable material 
to prevent postoperative peritoneal adhesions. However, its use as abdominal meshes is 
restricted by its gelloid properties.
Silveira et al.[67] developed two distinct types of BC meshes, a compacted one and a 
perforated one, and compared them with ePTFE meshes in terms of their in vivo tissue 
response. The in vivo evaluation was done using Wistar rats by inducing an acute muscle 
aponeurotic effect. The results showed that perforated BC membranes exhibited an 
improved performance, explained by its effective integration in host tissue and tissue 
remodeling induction effect, as well as due to its suitable biomechanical properties. Lai 
et al.[107] developed and evaluated a novel TEMPO-mediated modified bacterial cellulose 
(TBC) mesh to act as an anti-adhesion mesh for hernia repair. The TBC was laser 
perforated to originate isotropic, flat and stable structures, which avoided deformation 
under pressure. Comparatively to polypropylene mesh (the most widely used in these 
cases), the prepared mesh showed preferential adsorption of bovine serum albumin (BSA) 
and enhanced expression of collagen type I in fibroblasts. Furthermore, TBC mesh was 
found to cause less inflammation and to be surrounded by freshly formed connective 
tissue, constituted by collagen type I after implantation in rabbits for 1 week.
2.2.8. Tympanic membrane
Tympanic membrane (TM) perforations are a usual problem in otology and can be caused 
by physical external trauma or infection of the middle ear.[108] The TM has high 
regeneration ability, often resulting in spontaneous healing of acute perforations. 
However, in some cases, TM perforations are not able to heal without surgical 
intervention.[109] Myringoplasty is the reconstructive surgery for reparations of TM 
perforations.[110] Temporalis fascia is probably the most used tissue for myringoplasty, 
however, its use shows some drawbacks.[111] Thus, BC has been emerging as a promising 

































































material to replace temporalis fascia in this kind of intervention. This calls for a deep 
investigation of the effects of its application in humans[112] and a comparison to the use 
of the “standard” material, temporalis fascia.[113]
Biskin et al.[112] analyzed the clinical records of 12 patients (16 ears) who underwent 
myringoplasty using BC and observed that BC grafts did not induce any complication, 
such as granulation tissue formation or infection in any patient. Furthermore, they 
concluded that BC graft material led to a high success rate in small TM perforations, and 
was a safe, inexpensive and easy to use.
In this previous study, BC was presented as a safe and biocompatible alternative to 
temporalis fascia, and then, the need for comparing both have arisen. To fill this gap, 
Silveira et al.[113] performed a randomized clinical trial to compare BC and temporalis 
fascia grafts on the following parameters: time of epithelialization, surgical time, 
hospitalization costs and rate of closure of the TM perforation. The rate of TM perforation 
closure was analogous in both groups. Concerning the surgical time and hospitalization 
costs, BC showed to be superior to temporalis fascia (14.06 minutes and R$ 600 of BC, 
against 76.50 minutes and R$ 7778 of temporalis fascia), indicating that BC can be a 
good graft material for myringoplasty.
Another already used autogenous graft in several surgeries, including myringoplasty, is 
fat.[114] To compare BC, fat and temporalis fascia grafts, Mandour et al.[115] performed a 
prospective randomized trial. Similarly, to the previously mentioned studies, this team 
found that BC exhibited shorter surgery times, and an improved hearing and healing, 
regarding temporalis fascia and fat grafts.
2.2.9. Cartilage regeneration
Cartilage is a connective tissue comprised mainly by chondrocytes and a highly complex 
ECM, which contains collagen, glycosaminoglycans, laminin, elastin, fibronectin, and 
water. This type of tissue is found in several parts of the body, namely in the joints, ear, 
trachea, intervertebral discs and ribs. Cartilage defects can have several distinct onsets, 
such as aging, developmental disorder, sports injuries, joint injury and can cause joint 
pain, and sometimes loss of mobility. As a result of its avascular nature and low mitotic 
activity, cartilage exhibits a poor regenerative ability. Nowadays, cartilage defects are 
treated with autogenous cartilage grafts and prostheses. However, as it is well-known, 

































































these present several drawbacks.[116,117] Thus, BC and its composites have been widely 
studied as a material for tissue engineered scaffolds. 
Akaraonye et al.[118] developed a BC-poly(3-hydroxybutyrate) (P(3HB)) 3D composite 
scaffold, using sucrose as a porogen, with good dispersion and strong adhesion between 
BC and P(3HB). The resulting 3D scaffold exhibited improved load-bearing properties, 
high surface area-to-volume ratio, regular distribution of pore diameter and 
morphological resemblances with ECM. The high porosity of the scaffolds culminated in 
the infiltration and migration of mouse chondrogenic ATDC5 cells deep into the scaffold 
material. Furthermore, it was found an enhanced cell attachment and proliferation, as well 
as the maintenance of the chondrocyte phenotype.
Using a different approach, Horbert et al.[119] developed BC implants by 3D laser 
perforation and studied the regenerative capacity of the implants loaded with cells and 
free in a standardized bovine cartilage punch model. The 3D perforation allowed the 
ingrowth and movement of chondrocytes through the implant network, which helped the 
long-term performance of the implant. The cell-loading improved its performance by 
quickening cell colonization. The gradual increase of cell seeding, matrix deposition, and 
chondrogenic differentiation suggested the beginning of cartilage regeneration.
Taking advantage of the mechanical properties and structural similarity between BC and 
ECM, Wang et al.[120] designed ECM-mimicking microcarriers (

































































Figure 3). They also incorporated hydroxylysine (DHYL), which is an important collagen 
type II component, chitosan, and hyaluronic acid. The nanofibrous microcarriers (NF-
MCs) were cultured with bone marrow-derived mesenchymal stem cells (BMSCs) in a 
rotary cell culture system for 21 days to form the cartilage microtissues. With this 
innovative approach, they achieved a fine-tuning of porosity, pore size, mechanical 
properties, fiber diameter, and bioabsorption of NF-MCs. The NF-MCs showed a good 
ability for cell proliferation and differentiation. The prepared cartilage microtissues were 
implanted into a critical-size knee articular cartilage defect in mice and exhibited a good 
ability on the repair of cartilage tissue.

































































Wu et al.[121] incorporated lotus root starch in situ into BC to improve its biocompatibility. 
At the same time, spherical agarose particles were used to create a homogeneous porous 
network. Finally, through mineralization, spherical hydroxyapatite (HA) crystals were 
formed on the scaffold surface. The prepared composite scaffold enabled an improved 
proliferation of chondrocytes and higher total cell number. Moreover, the interconnected 
porous architecture of the scaffold enables efficient cell penetration, culminating in a 
good 3D cell distribution.
Zhu et al.[122] developed a double network structure prepared by 
1-ethyl-3-(3-(dimethylamino)propyl) carbodiimide hydrochloride (EDC) and N-hydroxy 
succinimide (NHS) mediated lysine cross-linking of poly(γ-glutamic acid) (PGA) and 
sodium alginate ionically cross-linked (Figure 4). To improve the mechanical properties 
of this double-network structure, they incorporated BC. Moreover, the authors designed 
a bilayer structure: a nonporous top layer and a porous bottom layer, which intended to 
mimic osteochondral tissues. Finally, HA microparticles were introduced in the top layer 
to stimulate cartilage matrix deposition, and HA nanocrystals in the bottom layer to 
stimulate osteogenesis and compression modulus. This composite scaffold presented a 
compression modulus similar to that of native articular cartilage and the swelling behavior 
was suitable for application in osteochondral tissue regeneration. Furthermore, the 
prepared scaffold exhibited good repair ability in osteochondral defect model of rabbits.
Another example that highlights the efforts made to combine the advantageous properties 
of BC and HA is the work developed by Kumbhar et al.[123]. In this work, they prepared 
a bilayer composite comprised of two BC composites: BC-HA and 
BC-glycosaminoglycans. In vitro assays with osteoblasts and human articular 
chondrocytes evidenced that the developed scaffolds could support cell attachment and 
proliferation. Furthermore, the in vivo tests were performed through implantation of the 
prepared scaffolds in osteochondral defects created in rat knees. These experiments 
indicated that the scaffolds allowed tissue ingrowth, accelerated the regeneration of 
articular cartilage and subchondral bone, as well as induced no immunological or 
inflammation reactions. Moreover, micro-computed tomography results evidenced that 
the ratio of bone volume-to-tissue volume and bone mineral density were significantly 
increased in the rats that received the scaffolds relatively to the control ones.

































































In a distinct study, Yang et al.[124] developed a new strategy for the preparation of 3D 
structures mimicking intervertebral discs (
Figure 5). This strategy involved the cultivation of Acetobacter xylinum in a 
micropatterned polydimethylsiloxane (PDMS) template. This micropatterned BC 
membrane was then rolled to form the annulus fibrous part of the intervertebral disk. 
Subsequently, the core of the rolled BC membrane was filled with a collagen solution to 
mimic, after gelation, the nucleus pulposus. The in vitro studies indicated good 
biocompatibility of the composites. Furthermore, in vivo tests on rats demonstrated that 

































































the implant developed presents excellent shape maintenance, tissue integration, hydration, 
flexibility, and mechanical support, creating a segment able to move.
2.2.10. Bone regeneration
Clinical conditions, such as tumors, trauma, and diseases (osteitis and osteomyelitis) have 
highlighted the importance of bone regeneration. Tissue engineering has been a highly 
studied alternative to conventional therapeutics, such as autografts, xenografts, and 
allografts.[15] As a result of its physicochemical properties, several BC composites and 
strategies using this type of material have been studied. 
One of the materials intensively studied for conjugation with BC was HA. HA 
[Ca10(PO4)6(OH)2], is the main non-organic component of bone.[125] HA exhibits a 
chemical and crystallographic structure analogous to the one of the bone and has been 
exhaustively studied for bone regeneration purposes. Moreover, HA has been known by 
its bioabsorbability, biocompatibility, bone-bonding ability, good osteoconductivity and 
bone mimicking crystalline structure.[15] Examples of the research done in the last years 
encompassing BC and HA are listed in Table 3. A specific example is a work developed 
by Hu et al.[126] where they prepared a bioabsorbable BC-HA composite through the 
immersion of BC membrane in an HA solution prepared in saturated synthetic body fluid 
(SBF) (1.0x) instead of oversaturated SBF (1.5x). This modification to the common 
procedure made it easier and proved to improve the total amount of calcium phosphates 
bounded to BC. The bioabsorbability was conferred by the incorporation of cellulosic 
enzymes, and in vitro bioabsorbability assays exhibited 96 % of glucose release, 
indicating an almost complete degradation of the scaffold. Furthermore, the scaffold 
prepared in saturated SBF exhibited improved biocompatibility than the scaffold prepared 
using oversaturated SBF.
As a result of its 3D structure that mimics the ECM, BC can also be used as a template 
for the formation of inorganic scaffolds.[127–133] Although, this topic is not the main focus 
of this review, for a better comprehension of this thematic we suggest the reading of the 
work developed by Salama.[134] Other examples of BC composites, new processing 
methodologies and in vitro and in vivo studies, aiming at contributing to enhancing bone 
regeneration are presented in Table 4.


































































The interest in using BC in the design and development of materials for biomedical 
applications has increasingly grown over the past years. Although BC is not naturally 
bioabsorbable, it has many other characteristics of interest that are mandatory for the 
development of this kind of products, being these characteristics mainly its 
biocompatibility, low cytotoxicity, very high water holding capacity and superior 
mechanical properties. By chemical modification or simple conjugation with other 
materials, BC characteristics can be further improved to meet the proper demands of the 
applications of interest. These applications can be the development of wound dressing 
and healing patches, design of drug (and other molecules) delivery systems, and the 
preparation of implants and grafts for very different parts of the organism. Over this 
review, BC has shown to be a material from which better and more efficient materials can 
be produced, in some cases, comparing to ones in the market, in other cases, better than 
previous “versions” of BC-based materials. As a result of BC versatility and 
customization, in the years to come, with the surge of new technology, BC will be more 
relevant in the biomedical area. New and cost-effective drug delivery systems will be 
developed. BC-based patches, scaffolds, and grafts for both internal and external use, for 
wound healing, tissue engineering, and regenerative medicine, will be refined to better 
meet the needs of each application, whereas there will be always the challenge of 
modifying BC without losing its properties of interest.
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Table 1. Summary of BC-based formulations for drug and other molecules delivery systems.
Formulation Cargo Outcome References
BC incorporated with Poloxamers Octenidine Long-term drug release that lasted 8 days [135]
BC immersed in drug solution Benzalconium chloride Sustained release of the drug for at least 24 h [40]
Drug or complex incorporated in 
mono and multilayer BC films
Scrophularia striata extract or a 
complex also containing 
β-cyclodextrin
Films showed antioxidant activity. Addition of β-cyclodextrin controlled the 
drug release. Lasting drug release was also observed in the multilayered films
[45]
Film of sodium carboxymethyl 
cellulose reinforced with BC
Ibuprofen Controlled drug release on higher contents of BC [136]
BC soaked with the ionic liquids 
and dried at room temperature in 
a nitrogen atmosphere
Ionic liquids based on phenolic acids Sustained release through the human skin. High antioxidant and anti-
inflammatory activity.
[51]
BC-gelatin hydrogel prepared 
through copolymerization and 
loaded with drug
Methylene blue BC-gelatin hydrogel showed a more controlled drug release than gelatin 
hydrogel
[137]
Surface modified BC with acetic 
anhydride, and dried in different 
fashions
Famotidine and tizanidine Different formulations showed different release ratios. Freeze-dried 
formulations revealed better drug sustaining for the drug with lower solubility 
in water
[52]
BC films modified with 
methoxylated pectin
Albumin and Levofloxacin Controlled release of both molecules. Levofloxacin cytotoxicity was reduced [50]
BC loaded with antibiotic Tetracycline hydrochloride Display controlled release, after an initial burst release of the drug and 
antibacterial activity
[43]
Drug-loaded 12 mm diameter BC 
tablets
Famotidine and tizanidine Superior burst release drug delivery characteristics [49]
Hollow BC spheres loaded with 
the drug
Fluorescein isothiocyanate-dextran Drug burst release [18]
Capsule shells of pure BC or 
conjugated with starch, 
hydroxypropylmethylcellulose or 
carboxymethyl cellulose
Salbutamol sulfate Burst release was observed on BC only capsules. Other capsules showed 
controlled release, and the ones formulated with carboxymethyl cellulose 
showed longer drug release over 6 h
[41]
Gelatin/BC hydrogel containing 
magnetic nanoparticles
Methylene blue Triple responsive material: drug release with temperature, low pH and 
magnetic field.
[47]
BC-PEDOT core-shell hybrid 
fibers (BC dip-coated with 
PEDOT)
Diclofenac sodium Electroresponsive release of the drug [48]
Poly(N-methacryloyl glycine) 
polymerized within BC
Diclofenac pH-Sensitive (drug retention at pH 2.1 and release at 7.4) [46]
Graphene oxide uniformly 
embedded into BC
Ibuprofen Controlled release and pH sensitive release of the drug [138]

































































pH-Responsive BC microparticles 
for insulin oral administration
Insulin BC protected insulin from enzymes and adhered to intestine [42]
BC nanowhiskers modified to 
become anionic, to be DNA 
vectors
Plasmid DNA In vitro studies showed DNA transfection [139]
Curcumin-soaked BC. Dried post-
soaking
Curcumin Antibacterial, antifungal and anticancer activity [44]
BC produced with media 
containing alginate, forming a 
composite
Doxorubicin Increased toxicity of doxorubicin over cancer cells [140]
BC: bacterial cellulose; PEDOT: poly(3,4-ethylenedioxythiophene).

































































Table 2. Summary of the various in vivo studies with BC or BC-based dressings for wound healing purposes.
Formulation Wound type Outcome References
BC containing vaccarin. Full thickness wound BC-vaccarin membranes exhibited faster and better wound healing properties
[55]
BC-dextran hydrogel composite Full thickness wound
Dextran promoted fibroblast cell growth in the proliferation stage and helps skin 
maturation in the remodeling stage, accelerating of the wound healing process
[59]
BC-collagen blended hydrogel. Full thickness wound BC-collagen hydrogel promoted a faster and better healing
[60]




Both standalone hydrogel and hydrogel containing cells sped-up the healing process. 
The fastest one was the hydrogel containing cells
[61]
BC containing Zingiber officinale root extract Full thickness wound
BC containing Zingiber officinale root aqueous extract was slower at healing the 
wounds than the components alone, although showed better healing 
[141]
Standalone Nanoskin® (BC-based nanocomposite) 
or gelatin-covered Nanoskin®
Full thickness 
wound Both BC-based grafts had better healing performance over the autologous skin graft
[142]
BC scaffold with porogens of gelatin Full thickness wound
After 2 weeks, the wounds treated with porogel BC were healed, comparing to the 
60% wound closure of the ones treated with BC only
[143]
Hollow BC microspheres Full thickness wound BC hollow spheres showed a faster healing than both BC microspheres and bulk BC
[17]
BC with a pattern of 10 μm stripes Deep-skin injury Patterned BC inhibited the inflammatory response and reduced the accumulation of fibroblasts, significantly decreasing the scar size, comparing to nonpatterned BC
[64]




pH affected the healing efficiency of natural BC, being the acidic one with the best 
healing efficiency
[66]




No difference in wound healing capacity or speed, however the BC-based dressings 
made the wounds much less painful for the patients
[65]
BC containing lidocaine Third-degree burns Loading BC with lidocaine does not interfere with BC natural wound healing ability
[144]
BC-acrylamide hydrogel microparticles Partial-thickness burns
The hydrogel accelerated the healing process by promoting re-epithelialization and 
proliferation of fibroblasts
[145]
BC dressing containing polyhexamethylene 
biguanide and silk sericin
Full thickness 
wound Composite showed antimicrobial activity, and showed faster healing than Bactigras
® [56]
BC containing Amoxicillin Full thickness wound BC containing antibiotic showed faster healing 
[53]
BC containing TiO2 nanoparticles
Third-degree 
burns
The dressing showed antimicrobial activity and enhanced wound healing effect, with 
re-epithelization and angiogenesis
[57]
BC containing ZnO nanoparticles Third-degree burns The dressing showed antimicrobial activity and enhanced wound healing effect
[58]

































































BC containing thymol Third-degree burns The dressing showed antimicrobial activity and enhanced wound healing effect
[146]
BC containing different kinds of MMTs: MMT, 
Cu-MMT, Na-MMT or Ca-MMT
Partial-thickness 
burns The dressings showed antimicrobial activity and enhanced wound healing effect
[147]
BC-chitosan biocomposites covered with silk 
fibroin or silk fibroin/phosphatidylcholine, loaded 
with vitamin K, protamine sulfate or kaolin
Femoral artery 
injury
Except for the hemostatic dressings loaded with kaolin, these composites are superior 
at controlling hemorrhage compared to the standard gauze on both healthy and 
diabetic rat models
[62,63]
BC: bacterial cellulose; MMT: montmorillonite.

































































Table 3. BC-HA composites for bone regeneration.




Composites were prepared by immersion of the BC membrane 
in a HA solution in saturated SBF and subsequent immersion in 
the enzyme solution.
Composite preparation strategy improves the calcium phosphates molecules 
formed in the composite; almost complete in vitro degradation and good 





BC scaffolds prepared through emulsion freeze-drying were 
immersed in a gelatin solution. Subsequently, BC-gelatin was 
immersed in procyanidin solution for cross-linking, and then 
soaked in a CaCl2 solution (for HA deposition).
Scaffolds exhibit improved mechanical properties, adhesion, viability, 
osteogenic differentiation, and proliferation of human BMSCs. In vivo 
studies with nude mice and rabbits show enhanced bone formation when 




Construction of a double-network by incorporation of nano-HA 
particles in BC nodules and subsequent incorporation of gelatin. 




Microporous BC scaffolds prepared by laser patterning were 
oxidized using sodium periodate and then mineralized with 
nano-HA by immersion in calcium and phosphate solutions.
Scaffold exhibit in vitro degradation of 13-25 %. Furthermore, human 




and OGP and 
OGP(10-14)
Ap was integrated in BC-collagen composites by in situ 
precipitation. OGP and OGP(10-14) were incorporated by 
adsorption. 
Composite induces cell growth at early time points relatively to BC-Ap 




Nano-HA was deposited in the BC membrane by a biomimetic 
approach. BMSCs were then seeded and allowed to proliferate 
and differentiate in the prepared scaffolds.
BC-(nano-HA) scaffolds show good biocompatibility, enhanced 
proliferation of BMSCs and induction of osteogenic differentiation through 
modulation of p38 signal transduction pathway. The composites seem to 
significantly improve the bone formation and osteogenic ability in vivo.
[152]
HA and SF
Comparison between BC-HA and BC-HA-SF composites, using 
SF from different sources. HA was initially incorporated in the 
BC trough immersion in a acetic acid solution containing 
Ca(NO3)2∙4H2O and (NH4)2HPO4, and precipitation was induced 
by NH3-treatment. The BC-HA composites were finally soaked 
in the respective SF solutions.
BC-HA-Antheraea yamamai SF exhibited improved mechanical strength, 
in vitro cytocompatibility and induced a higher cell proliferation than 
BC-HA-Bombyx mori SF.
[153]




































































Addition of chondroitin sulfate to the fermentation medium 
followed by a biomimetic process for the precipitation of 
heterogeneous calcium phosphate. 




-Tri-calcium phosphate, HA, PVP, carboxymethylcellulose 
and/or BC, PEG, agar, glycerin and water were processed by 
solvent casting method and the hydrogels formed by physical 
cross-linking. Filling of the BC-based hydrogel with calcium 
phosphate and CaCO3 was performed trough the in vitro 
mineralization process. 
The hydrogel scaffolds exhibit a compressive strength value 
(0.24-0.60 MPa) like the trabecular bones and anti-bacterial activity against 
S. aureus. When incubated with the prepared materials, the Lep-3 cells show 






SA, BC nanocrystals, and HA were initially treated in solution 
and D-glucono--lactone was added as cross-linker. The 
prepared hydrogel was soaked alternately in a chitosan solution 
and in a gelatin solution. 
3D scaffolds exhibit enhanced compressive strength and regulate 
bioabsorption. In vitro assays with osteoblastic MC3T3-E1 cells indicate 
that the arginine-glycine-aspartic repetitive motifs of gelatin enhance the 






BC membrane was mixed with agarose and gelatin. This mixture 
was processed by emulsion freeze-drying technique to form a 
porous scaffold. The resulting material was immersed in a 
gelatin solution and subsequently in a procyanidin solution for 
cross-linking gelatin. The porous scaffolds were soaked in a 
CaCl2 solution and subsequently immersed in an SBF solution.
BC-gelatin-procyanidin-HA show increased mechanical properties over the 
BC, BC-gelatin, and BC-gelatin-procyanidin. In vitro assays with human 
BMSCs indicate that BC-gelatin-procyanidin-HA porous scaffold shows 
improved viability, adhesion, proliferation and osteogenic differentiation. 
In vivo tests with mice and rabbits also indicate that this scaffold has the 
best osteogenesis, relatively to the three other scaffolds.
[157]
Ap: apatite; BC: bacterial cellulose; BMSCs: bone marrow-derived mesenchymal stem cells; HA: hydroxyapatite; OGP: osteogenic growth factor; PEG: polyethyleneglycol; 
PVP: Polyvinylpyrrolidone; SA: sodium alginate; SBF: synthetic body fluid; SF: silk fibroin.

































































Table 4. BC composites, method and in vitro and in vivo studies regarding bone regeneration. 
Method Outcome References
Cross-linking of a mixture of disintegrated BC 
membrane, MWCNCs–COOH, sodium alginate and 
D-mannitol. 
The prepared scaffolds show an enhanced osteoblast viability, proliferation, and adhesion. [158]
Preparation of bioabsorbable BC membranes by 
electron beam irradiation.
Electron beam irradiation increased the bioabsorbability and increased the cell viability of NIH3T3. The 
treated BC membranes show an enhancement in the in vivo bone regeneration on calvarial defects in Sprague-
Dawley rats.
[159]
In vitro and in vivo comparison between 
bioabsorbable BC membranes treated by electron 
beam irradiation and collagen membranes. 
In vitro assays with NIH3T3 cells did not show statistically significant differences in terms of cell adhesion 
and proliferation. The differences obtained in the in vivo studies with beagle dogs were not statistically 
relevant regarding new bone area, bone-to-implant contact and remaining bone substitute volume.
[160]
BC nanoribbons and SF aqueous solutions were 
poured into molds, in different ratios, and freeze-dried 
with temperature gradients. 
The composites exhibit radial lamellar patterns and gradient lamellar gap distance, these features allow an 
eight-fold increase in compression modulus and six-fold enhancement in compression strength. Furthermore, 
the prepared scaffolds exhibit an enhanced in vitro bioactivity, proliferation, and bone-cell adhesion of 
MC3T3 cells.
[161]
Implantation of BC membranes with different 
thicknesses in rat calvarian defect models to study 
membranes’ suitable thickness for guided bone 
regeneration.
BC membrane with 0.10 mm of thickness exhibits the formation of the highest volume of new bone and the 
greater percentage of new bone area.
[162]
Ex situ modification of BC by immersion in fisetin 
solutions with different concentrations.
The BMSCs seeded in the BC-fisetin scaffold show an increase in cell viability and differentiation into 
osteoblasts.
[163]
Evaluation of BMSCs behavior when cultured in a BC 
membrane.
The BMSCs were able to adhere, expand, and biointegrate when cultured in a BC membrane. The BC 
membrane has low toxicity and cytotoxicity. 
[164]

































































Coating of Ti6Al7Nb scaffolds with BC by 
immersion in Komagataeibacter xylinus bacteria 
culture medium, and subsequent soaking in a 
gentamycin solution.
BC-coated scaffolds display a significantly lower cytotoxicity for osteoblasts and fibroblasts relatively to the 
non-coated implants. Furthermore, the incorporation of gentamycin inhibited the growth of Staphylococcus 
aureus.
[165]
BC: bacterial cellulose; BMSCs: bone marrow-derived mesenchymal stem cells; MWCNCs: multi-walled carbon nanotubes; SF: silk fibroin.

































































Figure 1. (a) Photographs showing the appearance of the BC membrane before and after the 
TEMPO-mediated oxidation, as well as the representation of the chemical alteration in the glucose 
units in cellulose. Scanning electron microscopy images of (b) BC membrane, (c) TEMPO-
mediated BC nanofibers, and (d) water in oil emulsion of TEMPO-mediated BC nanofibers 
deposited on porcine skin. Scale bar equals to 1 µm. Repr nted with permission from ref. [69].

































































Figure 2. Preparation and cell loading of the three-layered BC tube. (a) Scheme of the preparation 
process of the BC tube. (b) Scheme of the loading of three cell types on the BC membrane and its 
rolling into a three-layered cell-laden tube. (c) Photograph of a lyophilized BC tube. (d) 
Micrograph of the fluorescent staining of the different loaded cells. Reprinted with permission 
from ref. [73].

































































Figure 3. Illustration of the nanofibrous microcarriers mimicking the ECM. (a) Schematic 
representation of the steps involved in the preparation of the nanofibrous microcarriers. (b) Scheme 
illustrating the nanofibrous microcarriers and its composition, as well as scanning electron 
microscopy images. Reprinted with permission from ref. [120].

































































Figure 4. Schematic representation of the steps involved in the hydrogels formation and structures 
prepared. (a) Graphical representation of the formation of the hydrogels. (b) Stages of the 
formation of bilayer hydrogel scaffolds. (c) Graphic representation of the structure of the bilayer 
hydrogel. (d) Scanning electron microscopy images of the obtained scaffolds. Reprinted with 
permission from ref. [122].

































































Figure 5. (a) Schematic representation of the steps for production of the total intervertebral discs. 
Micropatterned BC was manufactured by fermentation of Acetobacter xylinum in a PDMS 
template with a micropattern of 10 µm microgrooves aligned in  30° direction in alternating 
neighboring regions. The micropatterned BC was rolled to form a multilamellar structured annulus 
fibrosus. Then, a type II collagen solution was injected in the hole of the annulus fibrosus prepared 
to form the nucleus pulposus. The prepared intervertebral disc was implanted in a rat model. (b) 
Schematic illustration of the fabrication of the micropatterned BC. Firstly, a PDMS template with 
a micropattern was produced based on a Si wafer through the replica molding method. 
Subsequently the bacteria were cultured in the PDMS template and the micropatterned BC 
membrane was created at the liquid-PDMS template interface. Reprinted with permission from 
ref. [124].
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In this review it is overviewed the latest state-of-the-art usage of bacterial cellulose (BC) on three 
important areas of the biomedical fields: delivery systems, wound dressing and healing materials, 
and tissue engineering for regenerative medicine. BC is a promising biopolymer that is shown to 
be an effective and versatile carrier for delivery systems, a safe and multi-customizable patch or 
graft for wound dressing and healing applications, and a material that can be further tuned to better 
adjust for each tissue engineering application.
Keywords: Bacterial cellulose; Biomedical applications; Drug delivery; Regenerative medicine; 
Wound healing
T. Carvalho, G. Guedes, F. L. Sousa, C. S. R. Freire, H. A. Santos
Latest advances on bacterial cellulose-based materials for wound healing, delivery systems 
and tissue engineering
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other notices displayed by the Wiley Materials. You may not license, rent, sell, loan,
lease, pledge, offer as security, transfer or assign the Wiley Materials on a stand-alone
basis, or any of the rights granted to you hereunder to any other person.
The Wiley Materials and all of the intellectual property rights therein shall at all times
remain the exclusive property of John Wiley & Sons Inc, the Wiley Companies, or
their respective licensors, and your interest therein is only that of having possession of
and the right to reproduce the Wiley Materials pursuant to Section 2 herein during the
continuance of this Agreement. You agree that you own no right, title or interest in or
to the Wiley Materials or any of the intellectual property rights therein. You shall have
no rights hereunder other than the license as provided for above in Section 2. No right,
license or interest to any trademark, trade name, service mark or other branding
("Marks") of WILEY or its licensors is granted hereunder, and you agree that you
shall not assert any such right, license or interest with respect thereto
NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY,
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS
OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED
BY YOU.
WILEY shall have the right to terminate this Agreement immediately upon breach of
this Agreement by you.
You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any breach
of this Agreement by you.
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT,
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE,
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER
OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN.
Should any provision of this Agreement be held by a court of competent jurisdiction
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to be illegal, invalid, or unenforceable, that provision shall be deemed amended to
achieve as nearly as possible the same economic effect as the original provision, and
the legality, validity and enforceability of the remaining provisions of this Agreement
shall not be affected or impaired thereby.
The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition
of this Agreement. No breach under this agreement shall be deemed waived or
excused by either party unless such waiver or consent is in writing signed by the party
granting such waiver or consent. The waiver by or consent of a party to a breach of
any provision of this Agreement shall not operate or be construed as a waiver of or
consent to any other or subsequent breach by such other party.
This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.
Any fee required for this permission shall be non-refundable after thirty (30) days
from receipt by the CCC.
These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes
all prior agreements and representations of the parties, oral or written. This Agreement
may not be amended except in writing signed by both parties. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal representatives,
and authorized assigns.
In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions,
these terms and conditions shall prevail.
WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms
and conditions.
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.
This Agreement shall be governed by and construed in accordance with the laws of
the State of New York, USA, without regards to such state's conflict of law rules. Any
legal action, suit or proceeding arising out of or relating to these Terms and Conditions
or the breach thereof shall be instituted in a court of competent jurisdiction in New
York County in the State of New York in the United States of America and each party
hereby consents and submits to the personal jurisdiction of such court, waives any
objection to venue in such court and consents to service of process by registered or
certified mail, return receipt requested, at the last known address of such party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
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journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
Creative Commons Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY
license permits commercial and non-
Creative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by commercial "for-profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online Library http://olabout.wiley.com/WileyCDA
/Section/id-410895.html
Other Terms and Conditions:
v1.10 Last updated September 2015
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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Title of the article Latest advances on bacterial cellulose-based materials for wound
healing, delivery systems and tissue engineering
Publication new article is in Biotechnology Journal
Publisher of the new article Wiley
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1. The publisher for this copyrighted material is Elsevier.  By clicking "accept" in
connection with completing this licensing transaction, you agree that the following terms
and conditions apply to this transaction (along with the Billing and Payment terms and
conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you
opened your Rightslink account and that are available at any time at
http://myaccount.copyright.com).
GENERAL TERMS
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to
the terms and conditions indicated.
3. Acknowledgement: If any part of the material to be used (for example, figures) has
appeared in our publication with credit or acknowledgement to another source, permission
must also be sought from that source.  If such permission is not obtained then that material
may not be included in your publication/copies. Suitable acknowledgement to the source
must be made, either as a footnote or in a reference list at the end of your publication, as
follows:
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE
SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with
permission from Elsevier."
4. Reproduction of this material is confined to the purpose and/or media for which
permission is hereby given.
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions
and/or any other alterations shall be made only with prior written authorization of Elsevier
Ltd. (Please contact Elsevier at permissions@elsevier.com). No modifications can be made
to any Lancet figures/tables and they must be reproduced in full.
6. If the permission fee for the requested use of our material is waived in this instance,
please be advised that your future requests for Elsevier materials may attract a fee.
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the
combination of (i) the license details provided by you and accepted in the course of this
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions.
8. License Contingent Upon Payment: While you may exercise the rights licensed
immediately upon issuance of the license at the end of the licensing process for the
transaction, provided that you have disclosed complete and accurate details of your proposed
use, no license is finally effective unless and until full payment is received from you (either
by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions.  If
full payment is not received on a timely basis, then any license preliminarily granted shall be
deemed automatically revoked and shall be void as if never granted.  Further, in the event
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that you breach any of these terms and conditions or any of CCC's Billing and Payment
terms and conditions, the license is automatically revoked and shall be void as if never
granted.  Use of materials as described in a revoked license, as well as any use of the
materials beyond the scope of an unrevoked license, may constitute copyright infringement
and publisher reserves the right to take any and all action to protect its copyright in the
materials.
9. Warranties: Publisher makes no representations or warranties with respect to the licensed
material.
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and
their respective officers, directors, employees and agents, from and against any and all
claims arising out of your use of the licensed material other than as specifically authorized
pursuant to this license.
11. No Transfer of License: This license is personal to you and may not be sublicensed,
assigned, or transferred by you to any other person without publisher's written permission.
12. No Amendment Except in Writing: This license may not be amended except in a writing
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any
purchase order, acknowledgment, check endorsement or other writing prepared by you,
which terms are inconsistent with these terms and conditions or CCC's Billing and Payment
terms and conditions.  These terms and conditions, together with CCC's Billing and Payment
terms and conditions (which are incorporated herein), comprise the entire agreement
between you and publisher (and CCC) concerning this licensing transaction.  In the event of
any conflict between your obligations established by these terms and conditions and those
established by CCC's Billing and Payment terms and conditions, these terms and conditions
shall control.
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described
in this License at their sole discretion, for any reason or no reason, with a full refund payable
to you.  Notice of such denial will be made using the contact information provided by you. 
Failure to receive such notice will not alter or invalidate the denial.  In no event will Elsevier
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage
incurred by you as a result of a denial of your permission request, other than a refund of the
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied
permissions.
LIMITED LICENSE
The following terms and conditions apply only to specific license types:
15. Translation: This permission is granted for non-exclusive world English rights only
unless your license was granted for translation rights. If you licensed translation rights you
may only translate this content into the languages you requested. A professional translator
must perform all translations and reproduce the content word for word preserving the
integrity of the article.
16. Posting licensed content on any Website: The following terms and conditions apply as
follows: Licensing material from an Elsevier journal: All content posted to the web site must
maintain the copyright information line on the bottom of each image; A hyper-text must be
included to the Homepage of the journal from which you are licensing at
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at
http://www.elsevier.com; Central Storage: This license does not include permission for a
scanned version of the material to be stored in a central repository such as that provided by
Heron/XanEdu.
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier
homepage at http://www.elsevier.com . All content posted to the web site must maintain the
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copyright information line on the bottom of each image.
Posting licensed content on Electronic reserve: In addition to the above the following
clauses are applicable: The web site must be password-protected and made available only to
bona fide students registered on a relevant course. This permission is granted for 1 year only.
You may obtain a new license for future website posting.
17. For journal authors: the following clauses are applicable in addition to the above:
Preprints:
A preprint is an author's own write-up of research results and analysis, it has not been peer-
reviewed, nor has it had any other value added to it by a publisher (such as formatting,
copyright, technical enhancement etc.).
Authors can share their preprints anywhere at any time. Preprints should not be added to or
enhanced in any way in order to appear more like, or to substitute for, the final versions of
articles however authors can update their preprints on arXiv or RePEc with their Accepted
Author Manuscript (see below).
If accepted for publication, we encourage authors to link from the preprint to their formal
publication via its DOI. Millions of researchers have access to the formal publications on
ScienceDirect, and so links will help users to find, access, cite and use the best available
version. Please note that Cell Press, The Lancet and some society-owned have different
preprint policies. Information on these policies is available on the journal homepage.
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an
article that has been accepted for publication and which typically includes author-
incorporated changes suggested during submission, peer review and editor-author
communications.
Authors can share their accepted author manuscript:
immediately
via their non-commercial person homepage or blog
by updating a preprint in arXiv or RePEc with the accepted manuscript
via their research institute or institutional repository for internal institutional
uses or as part of an invitation-only research collaboration work-group
directly by providing copies to their students or to research collaborators for
their personal use
for private scholarly sharing as part of an invitation-only work group on
commercial sites with which Elsevier has an agreement
After the embargo period
via non-commercial hosting platforms such as their institutional repository
via commercial sites with which Elsevier has an agreement
In all cases accepted manuscripts should:
link to the formal publication via its DOI
bear a CC-BY-NC-ND license - this is easy to do
if aggregated with other manuscripts, for example in a repository or other site, be
shared in alignment with our hosting policy not be added to or enhanced in any way to
appear more like, or to substitute for, the published journal article.
Published journal article (JPA): A published journal article (PJA) is the definitive final
record of published research that appears or will appear in the journal and embodies all
value-adding publishing activities including peer review co-ordination, copy-editing,
formatting, (if relevant) pagination and online enrichment.
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Policies for sharing publishing journal articles differ for subscription and gold open access
articles:
Subscription Articles: If you are an author, please share a link to your article rather than the
full-text. Millions of researchers have access to the formal publications on ScienceDirect,
and so links will help your users to find, access, cite, and use the best available version.
Theses and dissertations which contain embedded PJAs as part of the formal submission can
be posted publicly by the awarding institution with DOI links back to the formal
publications on ScienceDirect.
If you are affiliated with a library that subscribes to ScienceDirect you have additional
private sharing rights for others' research accessed under that agreement. This includes use
for classroom teaching and internal training at the institution (including use in course packs
and courseware programs), and inclusion of the article for grant funding purposes.
Gold Open Access Articles: May be shared according to the author-selected end-user
license and should contain a CrossMark logo, the end user license, and a DOI link to the
formal publication on ScienceDirect.
Please refer to Elsevier's posting policy for further information.
18. For book authors the following clauses are applicable in addition to the above:
Authors are permitted to place a brief summary of their work online only. You are not
allowed to download and post the published electronic version of your chapter, nor may you
scan the printed edition to create an electronic version. Posting to a repository: Authors are
permitted to post a summary of their chapter only in their institution's repository.
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be
submitted to your institution in either print or electronic form. Should your thesis be
published commercially, please reapply for permission. These requirements include
permission for the Library and Archives of Canada to supply single copies, on demand, of
the complete thesis and include permission for Proquest/UMI to supply single copies, on
demand, of the complete thesis. Should your thesis be published commercially, please
reapply for permission. Theses and dissertations which contain embedded PJAs as part of
the formal submission can be posted publicly by the awarding institution with DOI links
back to the formal publications on ScienceDirect.
Elsevier Open Access Terms and Conditions
You can publish open access with Elsevier in hundreds of open access journals or in nearly
2000 established subscription journals that support open access publishing. Permitted third
party re-use of these open access articles is defined by the author's choice of Creative
Commons user license. See our open access license policy for more information.
Terms & Conditions applicable to all Open Access articles published with Elsevier:
Any reuse of the article must not represent the author as endorsing the adaptation of the
article nor should the article be modified in such a way as to damage the author's honour or
reputation. If any changes have been made, such changes must be clearly indicated.
The author(s) must be appropriately credited and we ask that you include the end user
license and a DOI link to the formal publication on ScienceDirect.
If any part of the material to be used (for example, figures) has appeared in our publication
with credit or acknowledgement to another source it is the responsibility of the user to
ensure their reuse complies with the terms and conditions determined by the rights holder.
Additional Terms & Conditions applicable to each Creative Commons user license:
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new
works from the Article, to alter and revise the Article and to make commercial use of the
Article (including reuse and/or resale of the Article by commercial entities), provided the
user gives appropriate credit (with a link to the formal publication through the relevant
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DOI), provides a link to the license, indicates if changes were made and the licensor is not
represented as endorsing the use made of the work. The full details of the license are
available at http://creativecommons.org/licenses/by/4.0.
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts,
abstracts and new works from the Article, to alter and revise the Article, provided this is not
done for commercial purposes, and that the user gives appropriate credit (with a link to the
formal publication through the relevant DOI), provides a link to the license, indicates if
changes were made and the licensor is not represented as endorsing the use made of the
work. Further, any new works must be made available on the same conditions. The full
details of the license are available at http://creativecommons.org/licenses/by-nc-sa/4.0.
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article,
provided this is not done for commercial purposes and further does not permit distribution of
the Article if it is changed or edited in any way, and provided the user gives appropriate
credit (with a link to the formal publication through the relevant DOI), provides a link to the
license, and that the licensor is not represented as endorsing the use made of the work. The
full details of the license are available at http://creativecommons.org/licenses/by-nc-nd/4.0.
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY
NC ND license requires permission from Elsevier and will be subject to a fee.
Commercial reuse includes:
Associating advertising with the full text of the Article
Charging fees for document delivery or access
Article aggregation
Systematic distribution via e-mail lists or share buttons
Posting or linking by commercial companies for use by customers of those companies.
20. Other Conditions:
v1.9
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or
one of its group companies (each a"Wiley Company") or handled on behalf of a society with
which a Wiley Company has exclusive publishing rights in relation to a particular work
(collectively "WILEY"). By clicking "accept" in connection with completing this licensing
transaction, you agree that the following terms and conditions apply to this transaction
(along with the billing and payment terms and conditions established by the Copyright
Clearance Center Inc., ("CCC's Billing and Payment terms and conditions"), at the time that
you opened your RightsLink account (these are available at any time at
http://myaccount.copyright.com).
Terms and Conditions
The materials you have requested permission to reproduce or reuse (the "Wiley
Materials") are protected by copyright.
You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-
alone basis), non-transferable, worldwide, limited license to reproduce the Wiley
Materials for the purpose specified in the licensing process. This license, and any
CONTENT (PDF or image file) purchased as part of your order, is for a one-time
use only and limited to any maximum distribution number specified in the license.
The first instance of republication or reuse granted by this license must be completed
within two years of the date of the grant of this license (although copies prepared
before the end date may be distributed thereafter). The Wiley Materials shall not be
used in any other manner or for any other purpose, beyond what is granted in the
license. Permission is granted subject to an appropriate acknowledgement given to the
author, title of the material/book/journal and the publisher. You shall also duplicate the
copyright notice that appears in the Wiley publication in your use of the Wiley
Material. Permission is also granted on the understanding that nowhere in the text is a
previously published source acknowledged for all or part of this Wiley Material. Any
third party content is expressly excluded from this permission.
With respect to the Wiley Materials, all rights are reserved. Except as expressly
granted by the terms of the license, no part of the Wiley Materials may be copied,
modified, adapted (except for minor reformatting required by the new Publication),
translated, reproduced, transferred or distributed, in any form or by any means, and no
derivative works may be made based on the Wiley Materials without the prior
permission of the respective copyright owner.For STM Signatory Publishers
clearing permission under the terms of the STM Permissions Guidelines only, the
terms of the license are extended to include subsequent editions and for editions
in other languages, provided such editions are for the work as a whole in situ and
does not involve the separate exploitation of the permitted figures or extracts,
You may not alter, remove or suppress in any manner any copyright, trademark or
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other notices displayed by the Wiley Materials. You may not license, rent, sell, loan,
lease, pledge, offer as security, transfer or assign the Wiley Materials on a stand-alone
basis, or any of the rights granted to you hereunder to any other person.
The Wiley Materials and all of the intellectual property rights therein shall at all times
remain the exclusive property of John Wiley & Sons Inc, the Wiley Companies, or
their respective licensors, and your interest therein is only that of having possession of
and the right to reproduce the Wiley Materials pursuant to Section 2 herein during the
continuance of this Agreement. You agree that you own no right, title or interest in or
to the Wiley Materials or any of the intellectual property rights therein. You shall have
no rights hereunder other than the license as provided for above in Section 2. No right,
license or interest to any trademark, trade name, service mark or other branding
("Marks") of WILEY or its licensors is granted hereunder, and you agree that you
shall not assert any such right, license or interest with respect thereto
NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY,
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS
OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED
BY YOU.
WILEY shall have the right to terminate this Agreement immediately upon breach of
this Agreement by you.
You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any breach
of this Agreement by you.
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT,
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE,
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER
OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN.
Should any provision of this Agreement be held by a court of competent jurisdiction
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to be illegal, invalid, or unenforceable, that provision shall be deemed amended to
achieve as nearly as possible the same economic effect as the original provision, and
the legality, validity and enforceability of the remaining provisions of this Agreement
shall not be affected or impaired thereby.
The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition
of this Agreement. No breach under this agreement shall be deemed waived or
excused by either party unless such waiver or consent is in writing signed by the party
granting such waiver or consent. The waiver by or consent of a party to a breach of
any provision of this Agreement shall not operate or be construed as a waiver of or
consent to any other or subsequent breach by such other party.
This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.
Any fee required for this permission shall be non-refundable after thirty (30) days
from receipt by the CCC.
These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes
all prior agreements and representations of the parties, oral or written. This Agreement
may not be amended except in writing signed by both parties. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal representatives,
and authorized assigns.
In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions,
these terms and conditions shall prevail.
WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms
and conditions.
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.
This Agreement shall be governed by and construed in accordance with the laws of
the State of New York, USA, without regards to such state's conflict of law rules. Any
legal action, suit or proceeding arising out of or relating to these Terms and Conditions
or the breach thereof shall be instituted in a court of competent jurisdiction in New
York County in the State of New York in the United States of America and each party
hereby consents and submits to the personal jurisdiction of such court, waives any
objection to venue in such court and consents to service of process by registered or
certified mail, return receipt requested, at the last known address of such party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
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journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
Creative Commons Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY
license permits commercial and non-
Creative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by commercial "for-profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online Library http://olabout.wiley.com/WileyCDA
/Section/id-410895.html
Other Terms and Conditions:
v1.10 Last updated September 2015
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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